{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:57:21Z","timestamp":1784012241717,"version":"3.55.0"},"reference-count":69,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pulm. circ."],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although rare, pulmonary arterial hypertension (PAH) is associated with substantial morbidity and a median survival of approximately 7 years, even with treatment. Current medical therapies have a primarily vasodilatory effect and do not modify the underlying pathology of the disease. CS1 is a novel oral, controlled\u2010release formulation of valproic acid, which exhibits a multi\u2010targeted mode of action (pulmonary pressure reduction, reversal of vascular remodeling, anti\u2010inflammatory, anti\u2010fibrotic, and anti\u2010thrombotic) and therefore potential for disease modification and right ventricular modeling in patients with PAH. A Phase 1 study conducted in healthy volunteers indicated favorable safety and tolerability, with no increased risk of bleeding and significant reduction of plasminogen activator inhibitor 1. In an ongoing randomized Phase 2 clinical trial, three doses of open\u2010label CS1 administered for 12 weeks is evaluating the use of multiple outcome measures. The primary endpoint is safety and tolerability, as measured by the occurrence of adverse events. Secondary outcome measures include the use of the CardioMEMS\u2122 HF System, which provides a noninvasive method of monitoring pulmonary artery pressure, as well as cardiac magnetic resonance imaging and echocardiography. Other outcomes include changes in risk stratification (using the REVEAL 2.0 and REVEAL Lite 2 tools), patient reported outcomes, functional capacity, 6\u2010min\u00a0walk distance, actigraphy, and biomarkers. The pharmacokinetic profile of CS1 will also be evaluated. Overall, the novel design and unique, extensive clinical phenotyping of participants in this trial will provide ample evidence to inform the design of any future Phase 3 studies with CS1.<\/jats:p>","DOI":"10.1002\/pul2.12323","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:14:05Z","timestamp":1704291245000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CS1, a controlled\u2010release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-6236","authenticated-orcid":false,"given":"Raymond L.","family":"Benza","sequence":"first","affiliation":[{"name":"Ohio State Wexner Medical Center The Ohio State University Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Adamson","sequence":"additional","affiliation":[{"name":"Heart Failure Division Abbott Inc. Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Heart Icahn School of Medicine at Mount Sinai New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Frick","sequence":"additional","affiliation":[{"name":"Cereno Scientific Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Olsson","sequence":"additional","affiliation":[{"name":"Institute of Medicine University of Gothenburg Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Bergh","sequence":"additional","affiliation":[{"name":"Institute of Medicine University of Gothenburg Gothenburg Sweden"},{"name":"Early Clinical Development, Biopharmaceuticals Research and Development\u2014Cardiovascular Renal and Metabolism, AstraZeneca M\u00f6lndal Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Dahl\u00f6f","sequence":"additional","affiliation":[{"name":"Cereno Scientific Gothenburg Sweden"},{"name":"Institute of Medicine University of Gothenburg Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019894534"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1140"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.07.088"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02024-2021"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.117.003973"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1460"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.024969"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.781532"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases8020022"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00617-2020"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202108_26455"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.02.004"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.12.013"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2069"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01601-4"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.09.011"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.029024"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.632208"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00148310"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2022.2092095"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.01.983"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2010.08.002"},{"issue":"7","key":"e_1_2_12_26_1","first-page":"273","article-title":"The CardioMEMS heart failure sensor: a procedural guide for implanting physicians","volume":"28","author":"Shavelle D","year":"2016","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)60101-3"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00723-0"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01754-2"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.10.422"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00923-6"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13748"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1943"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.122.009116"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.06.010"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.103176"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69737-x"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00263.2015"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-09-0580"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117211"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13527"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-021-00617-2"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517060"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00743-1"},{"key":"e_1_2_12_45_1","unstructured":"Dilantin prescribing information. New York NY: Pfizer Inc.; revised March 2022."},{"key":"e_1_2_12_46_1","unstructured":"DepakoteER. Prescribing information. North Chicago IL: AbbVie Inc; revised February 2023."},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.17303\/jcvm.2019.5.202"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037059209077502"},{"key":"e_1_2_12_49_1","unstructured":"United States Food and Drug Administration. Summary of safety and effectiveness data CardioMEMS\u2122 HF System. May 28 2014.https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf10\/P100045b.pdf. Accessed Apr 20 2023."},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024277"},{"key":"e_1_2_12_51_1","unstructured":"US Food and Drug Administration. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July 2005.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. Accessed September 5 2023."},{"key":"e_1_2_12_52_1","unstructured":"National Institute for Health and Care Excellence. Health technology appraisal: drugs for the treatment of pulmonary arterial hypertension. Draft scope. October 2008.https:\/\/www.nice.org.uk\/guidance\/discontinued\/gid-tag382. Accessed September 5 2023."},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11435-x"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213558"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.118.004757"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.105890"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1213917"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1503184"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01908-2018"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3698oc"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00740-2017"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2022.08.006"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.113.001229"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.010"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.119.006863"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.08.013"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.10.077"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12097"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2021.07.027"}],"container-title":["Pulmonary Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pul2.12323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:35:35Z","timestamp":1711654535000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pul2.12323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/pul2.12323"],"URL":"https:\/\/doi.org\/10.1002\/pul2.12323","archive":["Portico"],"relation":{},"ISSN":["2045-8940","2045-8940"],"issn-type":[{"value":"2045-8940","type":"print"},{"value":"2045-8940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12323"}}